secukinumab 150 mg (2 injections per dose
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pyoderma Gangrenosum
Conditions
Pyoderma Gangrenosum
Trial Timeline
May 1, 2021 → Apr 1, 2022
NCT ID
NCT04274166About secukinumab 150 mg (2 injections per dose
secukinumab 150 mg (2 injections per dose is a phase 2 stage product being developed by Novartis for Pyoderma Gangrenosum. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04274166. Target conditions include Pyoderma Gangrenosum.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04274166 | Phase 2 | Withdrawn |
Competing Products
11 competing products in Pyoderma Gangrenosum
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| adalimumab | AbbVie | Phase 3 | 77 |
| sisomicin | Merck | Approved | 85 |
| Secukinumab | Novartis | Phase 1/2 | 41 |
| Deucravacitinib | Bristol Myers Squibb | Phase 1 | 32 |
| gevokizumab | XOMA | Phase 2 | 44 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 69 |
| gevokizumab | XOMA | Phase 3 | 69 |
| gevokizumab + Placebo + gevokizumab open-label | XOMA | Phase 3 | 69 |
| vilobelimab + Placebo | InflaRx | Phase 3 | 69 |
| vilobelimab | InflaRx | Phase 2 | 44 |